The skin care brand Devita has announced a new treatment for the psoriasis condition psorinosis that has been used in the past to treat patients.
Devita’s Skin Care treatment is a topical corticosteroid and anti-inflammatory cream, and is available at its online store for $70 (£46) per bottle.
“We are thrilled to share the breakthrough treatment for psoritis,” said Devita chief executive and founder, Arash Khan.
“This treatment is safe, effective and delivers immediate results, and has a proven track record of delivering lasting improvements in patients.”
Dr. Alva G. Khan, MD, PhD, from Harvard Medical School, has previously worked with Devitas.
Dr Khan has studied psorias treatment for decades, and was an expert in psorosis treatment at the University of Michigan.
He also worked with several of the company’s top dermatologists to develop the treatment.
Dr. Khan also spoke to the press about the product and explained how it works.
“The key to the development of this topical cortisone cream is the fact that the cream is infused with a proprietary gel, which is made from collagen.
This gel provides a non-greasy, non-inflammatory surface to the skin,” Dr Khan said.
“It allows the skin to get the most benefit from the topical corticeptone and antiinflammatory agents.”
The product is made of water-soluble, nonabsorbable collagen and has been tested in animals.
It is available in the US as a topical treatment and for patients with severe psoroids.
“For people with milder skin conditions, we also have a topical cream which has been proven to improve the skin’s overall health,” Dr. G.K. Khan added.
Dr G. K. Khan explained that while the company is currently working with a dermatologist who is currently performing tests to determine if the topical cream is safe for use in humans, it will continue to provide research and clinical trials on this topical treatment.
This treatment has already been approved by the US Food and Drug Administration.
“Devita has made a bold step to transform the face care industry by providing a treatment for a disease that is a global issue,” said Dr Khan.
The company also announced that the first batch of the treatment has been distributed to more than 40 million customers.
This is a significant milestone in its evolution, and demonstrates Devitas commitment to providing top quality care to its customers.
“We are excited to be one of the first dermatologists in the world to offer this powerful topical treatment for skin diseases,” Dr G Khan said, “The FDA has been very supportive and we look forward to providing the benefit to our patients and our colleagues at Harvard Medical school, in particular.”
Dr Khan added that the product has been on the market for a year, and the company has received feedback from customers.
“While we were waiting for the FDA approval, we were able to test the product, and we have been impressed with the results,” Dr K.
K Khan said in a statement.
“With more than 100 million customers, we know the benefits of Devita skin products.
This breakthrough is one of a kind for our dermatology industry.”
The FDA said in 2016 that it is looking to expand its use of topical cortiscan agents to include treatments for the other seven skin conditions and conditions that cause psoroiditis.
The agency said it has been monitoring the use of cortiscans for the past six years and that it was actively reviewing the potential for the topical skin care products to be approved.
The skin care company is also developing a skin cream for those with severe skin conditions.
A report from the Journal of the American Academy of Dermatology (JAAD) states that the use and prescription of topical skin creams is “increasingly the norm”.
The company is working with Dr. Ewa Duda from the University Hospital of Wroclaw in Poland to develop a topical skin cream that is effective against psoridiosis.
Duda and her team have also recently developed a skin care product that uses a proprietary blend of ingredients to treat psoronia.
Dr. Khan noted that the skin care and topical cortixan products will not cure psorids.
Devita’s latest treatment is also being tested in clinical trials and will be available for a limited time in stores later this year.
It is unknown when the first batches of the topical treatment will be ready for retail sale.